The Serum Institute of India expects WHO emergency-use authorization soon for the Oxford University/AstraZeneca coronavirus vaccine, which it is producing for mid and low income countries, its chief executive said.
"The emergency use licensure from the WHO (World Health Organization) should be available and coming through in the next week or two, hopefully, because we have submitted everything," Adar Poonawalla told the Reuters Next conference on Thursday.
Poonawalla also said his company, the world's biggest vaccine maker, would start stockpiling millions of doses of the Novavax coronavirus vaccine candidate from around April.
"It will be upwards of 40-50 million doses per month is what we are trying to stockpile of the Novavax product," he said.
The Serum Institute CEO said a special purpose vehicle housing its pandemic-related products should be valued at $12 billion to $13 billion.
"We are in a unique position to be able to make so many different vaccines at a huge volume and capacity," he said.
"For an investor to come in an at a $12-13 billion valuation, it will be a fantastic deal, leaving a lot of upside."
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
Climate Crisis Threatens To Exploit Division, Polarisation: WHO Chief 'Disease X' In Congo Revealed To Be Malaria, Authorities Issue Urgent Warning Doctor Who: Joy to the World OTT Release Date Revealed: Here's When and Where to Watch it Online "Congress Should Be Ready...": Mani Shankar Aiyar's Big INDIA Bloc Remark 3 Marriages, Rs 1.25 Crore: How 'Looting Bride' Targeted Rich Men Bashar Al-Assad's Wife Files For Divorce, Wants To Return To UK: Report "No Chief Minister Face, No Agenda": Arvind Kejriwal Counters BJP Attack Who Was Epigamia CEO Rohan Mirchandani, Who Died Of Cardiac Arrest At 41 140 Trillion Oceans Of Water Discovered In Deep Space Track Latest News Live on NDTV.com and get news updates from India and around the world.